Cipla antimalarial drugs flagged of to Rwanda

 

 

The company was awarded the PMI contract several months ago to manufacture and supply malaria treatments (Artemether Lumefantrine) to African countries and those outside Africa such as Myanmar which receives medicines funded by PMI.

 

"We are delighted to have been contracted to provide this service based on our intent of providing affordable quality medicines to patients in Africa and beyond. As a company, we are focused on making a difference to patients and saving lives, so this is a wonderful opportunity to do so," Nevin Bradford CiplaQCIL' s Chief Executive Officer said. 

 

"The partnership with PMI will not only improve health sectors in different African countries and beyond but also shows that we're focused on providing African solutions to African problems," Bradford added.

 

The President's Malaria Initiative was launched in 2005 with the goal of reducing malaria-related mortality by 50% across 15 high-burden countries in sub-Saharan Africa through a rapid scale-up of four proven and highly effective malaria prevention and treatment measures.

 

To help achieve this goal, PMI contracted Uganda's CiplaQCIL to supply malaria medicines to African and Southeast Asian countries.

 

Rwanda, like most African countries, is at a high risk of malaria, however, the country made remarkable progress in the fight against malaria from 2005-2012. During this period there was an 86% reduction in malaria incidence and a 74% reduction in malaria mortality.

 

Rwanda joined the PMI program in 2007. The Initiative announced plans for a five-country expansion adding programs in Burkina Faso, Cameroon, Côte d'Ivoire, Niger, and Sierra Leone according to a statement from quality chemicals.

 

"Malaria prevention and control remains a major U.S. foreign assistance objective and PMI's strategy fully aligns with the U.S. Government's vision of ending preventable child and maternal deaths and ending extreme poverty," the statement said.